{"entity":{"id":"nct07347951","kind":"trial","name":"A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer","aka":[],"tldr":"A phase 2 trial of bevacizumab (glioblastoma use) in colorectal cancer, run by First Affiliated Hospital of Wenzhou Medical University, now recruiting.","summary":"A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer is a phase 2, interventional study registered as NCT07347951 by First Affiliated Hospital of Wenzhou Medical University, with a registry enrolment figure of 30 participants, started 2025-12-01 and due to reach its primary completion in 2027-12-01. Interventions recorded: Short-course radiotherapy; CAPOX chemotherapy; Targeted therapy with bevacizumab; Serplulimab immunotherapy. Conditions listed: Locally Advanced Rectal Cancer (LARC). Primary outcome: Pathological complete response (pCR) rate. Colorectal eligibility wording from the registry: \"* Diagnosed via pelvic MRI and rectoscopy with a tumor located ≤10 cm from the anal verge, with a clinical stage of cT3-4N0/+M0, and lymph nodes confined within the mesorectum\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07347951","url":"https://clinicaltrials.gov/study/NCT07347951"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":["bevacizumab-glioma"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07347951","phase":"2","setting":"A Single-Center, Prospective, Phase II Clinical Study to Evaluate the Preliminary Efficacy and Safety of Short-Course Radiotherapy Followed by CAPOX Chemotherapy Combined With Serplulimab and Bevacizumab as Total Neoadjuvant Therapy for MSS-Type, Mid-Low Locally Advanced Rectal Cancer","sponsor":"First Affiliated Hospital of Wenzhou Medical University","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07347951/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}